Acer Therapeutics Inc., a pharmaceutical firm that specializes in the procurement, development, and marketing of treatments for severe and rare life-threatening illnesses, has a promising pipeline of products. The company is currently undertaking clinical trials on four candidates, including EDSIVO for the management of vascular Ehlers-Danlos Syndrome confirmed in patients with a type III collagen mutation, ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer, and OLPRUVA, a formulation of sodium phenylbutyrate for inborn errors of metabolism like maple syrup urine disease and urea cycle disorders. Acer Therapeutics has also signed licensing and option agreements with Sanofi and Relief for the acquisition of worldwide rights to Osanetant, a selective and non-peptide tachykinin NK3 receptor antagonist in progress, and the development, regulator clearance, and commercialization of OLPRUVA, respectively. Additionally, Acer also has an intellectual property agreement with Emory University for the worldwide application of a family of patents and patent requests relating to the management of conditioned fear and anxiety disorders, including post-traumatic stress disorder. Founded in 1991, Acer Therapeutics is based in Newton, Massachusetts.
Acer Therapeutics Inc.'s ticker is ACER
The company's shares trade on the NASDAQ stock exchange
They are based in Newton, Massachusetts
There are 11-50 employees working at Acer Therapeutics Inc.
It is https://www.acertx.com/
Acer Therapeutics Inc. is in the Healthcare sector
Acer Therapeutics Inc. is in the Biotechnology industry
The following five companies are Acer Therapeutics Inc.'s industry peers: